Therapeutic response and monitoring of antibody-mediated renal graft rejection
DOI:
https://doi.org/10.5281/zenodo.15178468Keywords:
Kidney Transplantation, Graft Rejection, AntibodiesAbstract
Background: Antibody-mediated renal graft rejection is one of the main causes of graft loss. Treatment is based on the removal of circulating antibodies, inhibition of residual antibodies, reduction of their formation, minimization of the alloresponse and terminal complement activation.
Objective: To assess the therapeutic response in patients who received intravenous immunoglobulin, plasmapheresis, steroid and rituximab as treatment for antibody-mediated renal rejection.
Material and methods: An applicative, prospective study was carried out in hospitalized patients under the care of a nephrology service with a diagnosis of antibody-mediated rejection of the renal graft according to BANFF. 20 patients were included in 1 year, the biopsy was reviewed in an effort to classify the type of antibody-mediated rejection and the response to treatment was evaluated to demonstrate whether there was stabilization or improvement in renal function at 12 months of follow-up.
Results: Using the Wilcoxon test, creatinine during the biopsy of the injected and creatinine 12 months after receiving the therapeutic regimen were compared. The Z value was −1.8, with a p = 0.069.
Conclusions: There was no difference in terms of stabilization or recovery of renal graft function after 12 months of receiving treatment for antibody-mediated rejection based on steroids, plasma exchanges, immunoglobulin and rituximab.
Downloads
References
1. Sánchez-Cedillo A, Cruz-Santiago J, Mariño-Rojas FB, et al. Carga de la enfer-medad: insuficiencia renal, diálisis-hemodiálisis y trasplante renal en México. Costo de la enfermedad. Rev Mex Traspl. 2020;9(1):15-25. doi: 10.35366/94025
2. Böhmig GA, Eskandary F, Doberer K, et al. The therapeutic challenge of late anti-body‐mediated kidney allograft rejection. Transplant International. 2019;32(8):775-88. doi: 10.1111/tri.13436
3. Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clini-cal Journal of the American Society of Nephrology. 2020;15(3):430-8. doi: 10.2215/CJN.11991019
4. Guzzi F, Cirillo L, Buti E, et al. Urinary biomarkers for diagnosis and prediction of acute kidney allograft rejection: a systematic review. International Journal of Mo-lecular Sciences. 2020;21(18):6889. doi: 10.3390/ijms21186889
5. Callemeyn J, Lamarthée B, Koenig A, et al. Allorecognition and the spectrum of kidney transplant rejection. Kidney International. 2022;101(4):692-710. doi: 10.1016/j.kint.2021.11.029
6. Van Loon E, Bernards J, Van Craenenbroeck AH, et al. The causes of kidney allo-graft failure: more than alloimmunity. A viewpoint article. Transplantation. 2020; 104(2):e46-56. doi: 10.1097/TP.0000000000003012
7. Goutaudier V, Dange R, Catar RA, et al; EU-TRAIN Consortium. Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN). Kidney International. 2024;106(5):943-60. doi: 10.1016/j.kint.2024.07.027
8. Hooper DK, Varnell Jr. CD, Rich K, et al. A medication adherence promotion sys-tem to reduce late kidney allograft rejection: a quality improvement study. Ameri-can Journal of Kidney Diseases. 2022;79(3):335-46. doi: 10.1053/j.ajkd.2021.06.021
9. Filippone EJ, Farber JL. Histologic antibody-mediated kidney allograft rejection in the absence of donor-specific HLA antibodies. Transplantation. 2021;105(11):e181-90. doi: 10.1097/TP.0000000000003797
10. Van Loon E, Gazut S, Yazdani S, et al. Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: a multicentre, prospective study. EBioMedicine. 2019;46:463-72.
11. Bestard O, Thaunat O, Bellini MI, et al. Alloimmune risk stratification for kidney transplant rejection. Transplant International. 2022;35:10138. doi: 10.3389/ti.2022.10138
12. Van Loon E, Senev A, Lerut E, et al. Assessing the complex causes of kidney allograft loss. Transplantation. 2020;104(12):2557-66. doi: 10.1097/TP.0000000000003192
13. Lai C, Chadban SJ, Loh Y, et al. Targeting inflammatory monocytes by immune-modifying nanoparticles prevents acute kidney allograft rejection. Kidney International. 2022;102(5):1090-102. doi: 10.1016/j.kint.2022.06.024
14. Yagisawa T, Tanaka T, Miyairi S, et al. In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection. Kidney International. 2019;95(2):350-62. doi: 10.1016/j.kint.2018.08.041
15. Jehn U, Schuette-Nuetgen K, Kentrup D, et al. Renal allograft rejection: Noninva-sive ultrasound‐and MRI‐based diagnostics. Contrast Media & Molecular Imag-ing,.2019(1):3568067. doi: 10.1155/2019/3568067
16. Lubetzky M, Tantisattamo E, Molnar MZ, et al. The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients. American Journal of Transplantation. 2021;21(9):2937-49. doi: 10.1111/ajt.16717
17. Doberer K, Kläger J, Gualdoni GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Trans-plantation. 2021;105(2):451-7. doi: 10.1097/TP.0000000000003247
18. Clayton PA, McDonald SP, Russ GR, et al. Long-term outcomes after acute rejec-tion in kidney transplant recipients: an ANZDATA analysis. Journal of the Ameri-can Society of Nephrology. 2019;30(9):1697-707. doi: 10.1681/ASN.2018111101
19. Josephson MA, Becker Y, Budde K, et al. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Im-proving Global Outcomes (KDIGO) Controversies Conference. Kidney interna-tional. 2023;104(6):1076-91. doi: 10.1016/j.kint.2023.05.010
20. Bunnapradist S, Homkrailas P, Ahmed E, et al. Using both the fraction and quanti-ty of donor-derived cell-free DNA to detect kidney allograft rejection. Journal of the American Society of Nephrology. 2021;32(10):2439-41. doi: 10.1681/ASN.2021050645
21. Mayer KA, Doberer K, Eskandary F, et al. New concepts in chronic antibody-mediated kidney allograft rejection: prevention and treatment. Current Opinion in Organ Transplantation. 2021;26(1):97-105. doi: 10.1097/MOT.0000000000000832
22. Yoo D, Goutaudier V, Divard G, et al. An automated histological classification sys-tem for precision diagnostics of kidney allografts. Nature Medicine. 2023;29(5):1211-20. doi: 10.1038/s41591-023-02323-6
23. Aguirre LE, Guzman ME, Lopes G, et al. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. The Oncologist. 2019;24(3):394-401. doi: 10.1634/theoncologist.2018-0195
24. Köhnke R, Kentrup D, Schütte-Nütgen K, et al. Update on imaging-based diagno-sis of acute renal allograft rejection. American Journal of Nuclear Medicine and Molecular Imaging. 2019;9(2):110.
25. Mohamadou I, Savoye E, Cohen F, et al. Effect of hydroxychloroquine treatment on kidney allograft rejection and graft failure. In Transplantation Proceedings. 2024; 56(6):1251-8. Elsevier. doi: 10.1016/j.transproceed.2024.05.027
26. Oweira H, Ramouz A, Ghamarnejad O, et al. Risk factors of rejection in renal transplant recipients: a narrative review. Journal of Clinical Medicine. 2022;11(5): 1392. doi: 10.3390/jcm11051392
27. Lim WH, Johnson DW, Teixeira-Pinto A, et al. Association between duration of de-layed graft function, acute rejection, and allograft outcome after deceased donor kidney transplantation. Transplantation. 2019;103(2):412-9. doi: 10.1097/TP.0000000000002275
28. Metter C, Torrealba JR. Pathology of the kidney allograft. In Seminars in Diagnos-tic Pathology. 2020;37(3):148-53. doi: 10.1053/j.semdp.2020.03.005
29. Davis S, Mohan S. Managing patients with failing kidney allograft: many questions remain. Clinical Journal of the American Society of Nephrology. 2022;17(3):444-51. doi: 10.2215/CJN.14620920
30. Alasfar S, Kodali L, Schinstock CA. Current therapies in kidney transplant rejec-tion. Journal of Clinical Medicine. 2023;12(15): 4927. doi: 10.3390/jcm12154927
Published
Issue
Section
License
Copyright (c) 2025 Revista Médica del Instituto Mexicano del Seguro Social
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
